23 results
Differential diagnosis of Lymphangitic Carcinomatosis. 
On the left multiple diseases showing septal thickening:
1. Lymphangitic carcinomatosis: irregular
Cardiogenic pulmonary ... Cardiogenic pulmonary ... #Clinical #Radiology ... #Pulmonary #CTChest ... #Differential #Comparison
Iron Deficiency in Congestive Heart Failure (CHF)

Iron deficiency (ID) in heart failure is a common comorbidity
Heart Failure (CHF ... TSAT < 20% Risk ... depot iron] Treatment ... #pharmacology # ... pathophysiology #cardiology
On the left another patient with alveolar edema at admission, which resolved after treatment.
When you scroll
another patient with alveolar ... resolved after treatment ... #Clinical #Radiology ... #CXR #CHF #Alveolar ... #Pulmonary #Edema
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
factors: Critical ... : 33% • Treatment ... : Age>60, CKD, CHF ... , and CXR with pulmonary ... hematology #diagnosis #comparison
Noninvasive Positive Pressure Ventilation (NIPPV)

Expiratory & Inspiratory Positive Airway Pressure
Both increase intrathoracic pressure, which can decrease
can "recruit" alveoli ... In CHF, decreases ... exacerbation (cardiogenic pulmonary ... patients (ie., CHF ... Of Clinical Worsening
Stage I - Redistribution
In a normal chest film with the patient standing erect, the pulmonary vessels
In daily clinical ... In these cases comparison ... during a period of CHF ... #Clinical #Radiology ... #CXR #CHF #Cephalization
Stage III - Alveolar edema
This stage is characterized by continued fluid leakage into the interstitium, which
After treatment ... redistribution of the pulmonary ... #Clinical #Radiology ... #CXR #CHF #Alveolar ... #Pulmonary #Edema
Heart failure with Reduced Ejection Fraction (HFrEF)
Clinical Presentation
1. Typical symptoms: dyspnea, orthopnea paroxysmal noctumal dyspnea, fatigue,
Fraction (HFrEF) Clinical ... Kerley B lines, alveolar ... endomyocardial biopsy Pharmacology ... diagnosis #management #cardiology ... #pharmacology #
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
reach the terminal alveoli ... taken up by the alveolar ... lymph nodes Risk ... characteristic features Clinical ... Inhibitor: • Risk
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
reach the terminal alveoli ... taken up by the alveolar ... lymph nodes Risk ... characteristic features Clinical ... Inhibitor: • Risk